The unique technology behind this biomarker will support clinical trials in better assessing the aggressiveness and development of a patient’s cancer, ultimately assisting in clinical decision-making for cancer treatments.
BOSTON (PRWEB) January 31, 2018
One Million Solutions in Health announces an opportunity to license science from the NIH: a new, groundbreaking biomarker measuring the effectiveness of cancer treatments and therapies in clinical trials.
One Million Solutions in Health has partnered with the United States' National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) and is seeking to spread awareness of NIH technologies and advances.
In this One Million Solutions in Health webinar entitled “NIH SPECIAL SERIES: Testing the efficacy of new cancer treatments in clinical trials using a unique biomarker", end users are provided with the opportunity to acquire knowledge about the latest science and technology directly from NIH scientists themselves. Users can also take part in One Million Solutions in Health's exclusive Signature Square process where they are able to assess the innovation, make inquiries and give open feedback to the scientists.
The unique technology behind this biomarker will support clinical trials in better assessing the aggressiveness and development of a patient’s cancer, ultimately assisting in clinical decision-making for cancer treatments. The potential behind this biomarker is noteworthy as patients ‘traditionally’ characterised as having Stage 1 cancer, may actually be concealing a fundamental disease which is much more malignant than anticipated. This could be the reason why certain patients who have been previously-diagnosed with having Stage 1 really have an earlier mortality than anticipated.
In clinical trials, this biomarker possesses the ability to more efficiently stratify patients who are entered into the clinical trial. More importantly, this biomarker could be used to test the responsiveness of the cancer to therapy or treatment throughout the progression of the therapeutic treatment.
Overall, the applications of this biomarker in clinical trials not only holds the potential to revolutionize oncology clinical trials, but also cancer care, by altering the current classification. Namely, the opportunity is to go beyond a classification system based on Stages and to be able to categorize cancer according to its aggressiveness.
If you would like to license this biomarker to evaluate cancer treatments and therapies in clinical trials, then this presentation is for you.
ABOUT ONE MILLION SOLUTIONS IN HEALTH
The goal of One Million Solutions in Health™ is to shape health care by sharing solutions and, importantly, to accelerate the discovery, development and delivery of innovative cures, treatments and preventative measures for patients around the world.
In this next year, we will be reviewing 1000's of new solutions and new scientific discoveries. By engaging scientists, entrepreneurs, investors, innovators, industry experts, health care professionals, and patients across various disciplines, and from around the world, we can utilize the power of the internet to disrupt things in a positive and transformative way to accelerate the movement of new solutions and scientific discoveries from the scientist to the patient.
We are on our way towards accelerating high-potential innovations, catalyzing investment and increasing awareness of, and support for, transformative ideas to improve health and save lives. By facilitating efforts to ensure organizations can Connect, Learn + Share, Innovate and Collaborate, our vision is to improve health care delivery, accelerate life sciences research, and share patient and consumer-focused ideas and solutions.
As a not-for-profit, we welcome your participation and are thrilled to have you be a part of this transformative journey!
Dawn Van Dam
Executive Director and CEO